Has Ashish Masih, MD received payments from drug or device companies?

Yes. Drug and device makers reported $168,081 in general payments to Ashish Masih, MD across 634 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Ashish Masih, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Ashish Masih, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Ashish Masih, MD

Neurology · Oklahoma City, OKNPI 1093857971

Payments from drug & device makers

$168,081in general payments, 2019–2025

Across 634 payments — averaging $265.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$151K
E.r. Squibb & Sons, L.L.C.$10K
UCB, Inc.$665
Lundbeck LLC$407
Pfizer$407
AstraZeneca$367
plus $5K from 42 others

What the payments were for

Speaking & faculty fees$140,07789%
Travel & lodging$7,4745%
Food & beverage$10,2286%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie(2 entities)	342	$151,277
E.r. Squibb & Sons, L.L.C.	3	$10,313
UCB, Inc.	36	$665
Lundbeck LLC	10	$407
Pfizer	21	$407
AstraZeneca	13	$367
Neurocrine Biosciences, Inc.	20	$352
Supernus Pharmaceuticals, Inc.	19	$323
Argenx US, Inc.	8	$290
Teva Pharmaceuticals USA, Inc.	13	$280
Novartis	15	$270
Livanova USA, Inc.	6	$228
Acadia Pharmaceuticals Inc	11	$218
Merz Pharmaceuticals, LLC	7	$201
Amgen	10	$196
Axsome Therapeutics, Inc.	5	$195
Lilly USA, LLC	9	$163
GE HealthCare	7	$162
Eisai Inc.	7	$159
MDD US Operations, LLC	3	$146
Genentech USA, Inc.	7	$140
SK Life Science, Inc.	5	$117
Catalyst Pharmaceuticals, Inc.	4	$108
Octapharma USA, Inc.	1	$90
Amneal Pharmaceuticals LLC	4	$87
Neurelis, Inc.	4	$87
Sanofi	4	$86
Alnylam Pharmaceuticals Inc.	3	$72
Acorda Therapeutics, Inc	4	$69
Jazz Pharmaceuticals Inc.	2	$66
Sunovion Pharmaceuticals Inc.	6	$61
Biogen	3	$60
Averitas Pharma Inc.	3	$52
CSL Behring	2	$48
TG Therapeutics, Inc.	2	$41
Bristol Myers Squibb	2	$34
Ipsen Biopharmaceuticals, Inc	1	$34
Corium, LLC	1	$28
ANI Pharmaceuticals, Inc.	1	$25
Otsuka America Pharmaceutical, Inc.	1	$23
Kyowa Kirin, Inc.	1	$21
NS Pharma, Inc.	1	$20
Mallinckrodt Enterprises LLC	1	$20
Otsuka Pharmaceutical Development & Commercialization, Inc.	1	$19
EMD Serono, Inc.	1	$18
Impel Pharmaceuticals Inc.	1	$16
Johnson & Johnson	1	$15
Sumitomo Pharma America, Inc.	2	$5

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

UBRELVY$128,485
QULIPTA$33,048
VYVGART$148
SOLIRIS$121
AIMOVIG$113
Symbravo$112
GOCOVRI$110
VYEPTI$107

How this compares

$168,081 in reported general payments places this provider in the 85th percentile of 152 neurology providers in Oklahoma.

See all neurology providers in Oklahoma →

Medicare billing

Part B allowed, 2024

$254,714

Medicare patients

756

Services billed

2,972

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Lacosamide	138	$10,948
Levetiracetam	150	$4,844
Memantine Hcl	178	$4,420
Gabapentin	211	$3,031
Memantine Hcl ErMemantine Hcl	11	$2,013
Primidone	81	$1,608
Carbamazepine ErCarbamazepine	12	$1,521
Donepezil Hcl	177	$1,146
Pregabalin	51	$864
Duloxetine Hcl	38	$803
Carbamazepine	16	$642
Carbidopa-LevodopaCarbidopa/Levodopa	47	$575
Lamotrigine	37	$408
Topiramate	44	$373
Phenobarbital	21	$285

Paid to pharmacies, not to this prescriber.

Other neurology in Oklahoma City

Gabriel PardoOklahoma City$10.3M
Cherian KarunapuzhaOklahoma City$4.1M
James BattisteOklahoma City$1.1M
Mariana VargaOklahoma City$670K
Marguerite ButcheeOklahoma City$324K
Chelsea BerkleyOklahoma City$277K
Evgeny SidorovOklahoma City$212K
Aaron FarrowOklahoma City$172K
Erika Santos HortaOklahoma City$93K
Christi PendergraftOklahoma City$73K

See the full list for Oklahoma →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →